| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J Taylor Harden, Nina Silverber. NIA outreach to minority and health disparity populations can a toolbox for recruitment and retention be far behind? Alzheimer disease and associated disorders. vol 24 Suppl. 2012-06-21. PMID:22720317. |
this article provides an introduction to a number of recruitment and retention tools in a national institute on aging health disparities toolbox and to this special edition on challenges and opportunities in recruitment and retention of minority populations in alzheimer disease and dementia research. |
2012-06-21 |
2023-08-12 |
Not clear |
| J Taylor Harden, Nina Silverber. NIA outreach to minority and health disparity populations can a toolbox for recruitment and retention be far behind? Alzheimer disease and associated disorders. vol 24 Suppl. 2012-06-21. PMID:22720317. |
the health disparities toolbox and health disparities resource persons network are described along with other more established resource tools including the alzheimer disease center education cores, alzheimer disease education and referral center, and resource centers for minority aging research. |
2012-06-21 |
2023-08-12 |
Not clear |
| Alexander L Chin, Selamawit Negash, Roy Hamilto. Diversity and disparity in dementia: the impact of ethnoracial differences in Alzheimer disease. Alzheimer disease and associated disorders. vol 25. issue 3. 2011-12-14. PMID:21399486. |
diversity and disparity in dementia: the impact of ethnoracial differences in alzheimer disease. |
2011-12-14 |
2023-08-12 |
Not clear |
| Jesse C Wiley, James S Meabon, Harald Frankowski, Elise A Smith, Leslayann C Schecterson, Mark Bothwell, Warren C Ladige. Phenylbutyric acid rescues endoplasmic reticulum stress-induced suppression of APP proteolysis and prevents apoptosis in neuronal cells. PloS one. vol 5. issue 2. 2010-09-30. PMID:20161760. |
the familial and sporadic forms of alzheimer's disease (ad) have an identical pathology with a severe disparity in the time of onset [1]. |
2010-09-30 |
2023-08-12 |
Not clear |
| Martha Perryman, Marisa Lewis, Patrick A River. Treatment disparities in medication prescribing for Alzheimer's: disease among ethnic groups. Journal of health care finance. vol 35. issue 4. 2010-07-29. PMID:20515010. |
treatment disparities in medication prescribing for alzheimer's: disease among ethnic groups. |
2010-07-29 |
2023-08-12 |
Not clear |
| Roberta Diaz Brinto. The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends in neurosciences. vol 31. issue 10. 2009-04-09. PMID:18774188. |
the healthy cell bias of estrogen action hypothesis provides a lens through which to assess disparities in outcomes across basic and clinical science and on which to predict outcomes of estrogen interventions for sustaining neurological health and preventing age-associated neurodegenerative diseases such as alzheimer's. |
2009-04-09 |
2023-08-12 |
Not clear |
| Roberta Diaz Brinto. Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease. Advanced drug delivery reviews. vol 60. issue 13-14. 2008-12-29. PMID:18647624. |
the healthy cell bias of estrogen action hypothesis provides a lens through which to assess the disparities in outcomes across the basic to clinical domains of scientific inquiry and on which to predict future applications of estrogen and hormone therapeutic interventions sustain neurological health and to prevent age-associated neurodegenerative diseases such as alzheimer's. |
2008-12-29 |
2023-08-12 |
Not clear |
| Sonja A Rasmussen, Nedra Whitehead, Sarah A Collier, Jaime L Fría. Setting a public health research agenda for Down syndrome: summary of a meeting sponsored by the Centers for Disease Control and Prevention and the National Down Syndrome Society. American journal of medical genetics. Part A. vol 146A. issue 23. 2008-12-12. PMID:19006076. |
the following were identified as priority areas for future public health research: identification of risk and preventive factors for physical health and cognitive outcomes, focusing on understanding the reasons for previously recognized disparities; improved understanding of comorbid conditions, including their prevalence, clinical variability, natural history, and optimal methods for their evaluation and treatment; better characterization of the natural history of cognition, language, and behavior; identification of mental health comorbidities and of risk and protective factors for their development; identification of strategies to improve enrollment in research studies; development of strategies for conveying up-to-date information to parents and health professionals; identification of interventions to improve cognition, language, mental health, and behavior; understanding the impact of educational and social services and supports; identification of improved methods for diagnosis of and interventions for alzheimer disease; and understanding the effects of different types of health care on outcomes. |
2008-12-12 |
2023-08-12 |
human |
| Derek M Griffith, Patrick A Griffit. Commentary on "Perspective on race and ethnicity in Alzheimer's disease research". Alzheimer's & dementia : the journal of the Alzheimer's Association. vol 4. issue 4. 2008-08-26. PMID:18631973. |
there are persistent disparities in alzheimer's disease by race and ethnicity that are not well understood. |
2008-08-26 |
2023-08-12 |
Not clear |
| Roberta Diaz Brinto. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action. Annals of the New York Academy of Sciences. vol 1052. 2006-06-29. PMID:16024751. |
the profound disparities between the largely positive basic science findings of gonadal steroid action in brain and the adverse outcomes of recent hormone therapy clinical trials in women who are either aged postmenopausal or postmenopausal with alzheimer's disease have led to an intense reassessment of gonadal hormone action and the model systems used in basic and clinical science. |
2006-06-29 |
2023-08-12 |
Not clear |
| Roberta D Brinto. Impact of estrogen therapy on Alzheimer's disease: a fork in the road? CNS drugs. vol 18. issue 7. 2004-07-12. PMID:15139797. |
a major question emerging from these studies is: how can there be such disparity between the basic science and epidemiological data that show that estrogen can protect neurons against degenerative insults and reduce the risk of alzheimer's disease and the recent data (from the women's health initiative memory study [whims] trial and the trial of estrogen treatment for alzheimer's disease), which show that hormone replacement therapy (hrt) showed no benefit and even a potential deleterious effect? |
2004-07-12 |
2023-08-12 |
Not clear |
| Steven D Edland, Susan Slager, Matthew Farre. Genetic association studies in Alzheimer's disease research: challenges and opportunities. Statistics in medicine. vol 23. issue 2. 2004-03-31. PMID:14716719. |
the disparity of findings in initial positive reports versus subsequent negative replication studies observed in the alzheimer's disease literature underscores this problem. |
2004-03-31 |
2023-08-12 |
human |
| . National Institutes of Health Center Grants. Final rule. Federal register. vol 68. issue 240. 2004-01-05. PMID:14674396. |
the national institutes of health (nih) is amending its regulations governing center grants to reflect their applicability to several new grant programs, including research on autism, alzheimer's disease, fragile x disease, and minority health disparities and other types of health disparities. |
2004-01-05 |
2023-08-12 |
Not clear |
| S G Post, J C Stuckey, P J Whitehouse, S Ollerton, C Durkin, D Robbins, S J Fallcree. A focus group on cognition-enhancing medications in Alzheimer disease: disparities between professionals and consumers. Alzheimer disease and associated disorders. vol 15. issue 2. 2002-02-13. PMID:11391089. |
a focus group on cognition-enhancing medications in alzheimer disease: disparities between professionals and consumers. |
2002-02-13 |
2023-08-12 |
Not clear |
| D R Grothe, S C Piscitelli, R Dukoff, T Fullerton, T Sunderland, S E Molcha. Penetration of tacrine into cerebrospinal fluid in patients with Alzheimer's disease. Journal of clinical psychopharmacology. vol 18. issue 1. 1998-04-02. PMID:9472847. |
the authors support that penetration of tacrine into csf is highly variable in patients with alzheimer's disease and that disparity in tacrine concentrations at the site of action may be one reason for conflicting results from studies of the efficacy of tacrine in alzheimer's disease. |
1998-04-02 |
2023-08-12 |
Not clear |
| A B Graves, E B Larson, L R White, E L Teng, A Homm. Opportunities and challenges in international collaborative epidemiologic research of dementia and its subtypes: studies between Japan and the U.S. International psychogeriatrics. vol 6. issue 2. 1995-03-24. PMID:7865708. |
the disparities in prevalence rates of dementia subtypes, particularly alzheimer's disease and multi-infarct dementia, are especially apparent in studies conducted in eastern and western countries. |
1995-03-24 |
2023-08-12 |
Not clear |
| S Singhrao, G Cole, W J Henderson, G R Newma. LR White embedding allows a multi-method approach to the analysis of brain tissue from patients with Alzheimer's disease. The Histochemical journal. vol 22. issue 5. 1992-03-18. PMID:1966829. |
light (lm) and electron (em) microscope comparisons of the cytochemistry and immunocytochemistry of neuritic plaques and neurofibrillary tangles, the main histopathological changes in the brains of alzheimer's disease sufferers, have been almost impossible because of the disparity between the two technologies. |
1992-03-18 |
2023-08-11 |
mouse |
| B J Quigley, N W Kowal. Substance P-like immunoreactive neurons are depleted in Alzheimer's disease cerebral cortex. Neuroscience. vol 41. issue 1. 1991-07-29. PMID:1711654. |
this disparity may be due to persistence of afferent projections which make a major contribution to substance p concentrations in cerebral cortex or to the high substance p content of dystrophic fibers in alzheimer's disease cortex. |
1991-07-29 |
2023-08-11 |
Not clear |